Skip to content

Testing Viton 99 Caplet to see if it helps boost energy and strengthen the immune system

Clinical Evaluation of Viton 99 Caplet as a Rejuvenator and Immunomodulator: A single arm open labelled clinical trial - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/090012
Enrollment
100
Registered
2025-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Dr Deodatta Bhadlikar
Lead Sponsor
Ban Labs Pvt Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.Healthy male and female adults with no chronic disease or conditions that would interfere with study participation or outcomes(eg cardiovascular autoimmune or metabolic disorders) 2.Ability and willingness to provide written informed consent and comply with all study procedures. 3.no history of immunodeficiency HIV or other conditions that would significantly affect immune function. 4.Participants must have a baseline physical performance score and cognitive function within the normal range fot their age group. 5.Participants on medications must have been on a stable regimen for at least 4 weeks prior to enrolment (excluding medications that may interfere with immune function or rejuvenation processes such as immunosuppressants). 6.Participants must agree not to take other immunomodulatory or rejuvenating supplements (e.g. other vitamins antioxidants or immune boosters) during the study period. 7.A BMI within the range of 18.5 to 30.0 kg per m . 8.Non-smokers or individuals who have not smoked for at least 6 months prior to enrolment. 9.No history of significant psychiatric disorders or any conditions that may interfere with the participants ability to engage in study activities or assessments.

Exclusion criteria

Exclusion criteria: 1.Chronic Health Conditions: Individuals with a history of serious chronic diseases such as cardiovascular diseases diabetes autoimmune disorders cancer or other conditions that may affect immune function or rejuvenation processes. 2.Immunodeficiency: Participants with a history of immune system disorders including HIV and AIDS primary or secondary immunodeficiencies or who are on immunosuppressive therapy (e.g.corticosteroids chemotherapy). 3.Pregnancy and Lactation: Pregnant or breastfeeding women, or individuals planning to become pregnant during the study period. 4.Severe Allergies: History of severe allergies or hypersensitivity to any components of Viton 99 Caplet. 5.Psychiatric Disorders: Individuals with a current or past history of significant psychiatric disorders, including major depressive disorder schizophrenia or other severe mental health conditions that could interfere with participation in the study. 6.Medications and Supplements: Use of medications or supplements that could significantly interfere with immune function cognitive function or physical performance (e.g. immunosuppressants anabolic steroids or cognitive-enhancing drugs) within 4 weeks prior to enrolment. 7.Recent Illness or Infection: Individuals who have had a serious infection or illness (including acute viral or bacterial infections) within the past 4 weeks prior to enrolment. 8.BMI Outside Normal Range: Participants with a Body Mass Index (BMI) less than 18.5 kg per m or greater than 30.0 kg per m . 9.Smoking or Substance Abuse: Current smokers, individuals who have smoked in the past 6 months or those with a history of substance abuse (including alcohol or recreational drugs). 10.Participation in Other Clinical Trials: Individuals who are currently participating in or have participated in another clinical trial involving an investigational drug or intervention within the last 30 days. 11.Inability to Follow Protocol: Any condition or situation that in the opinion of the investigator may interfere with the participants ability to comply with study procedures or pose a risk to the participants safety. Severe Gastrointestinal Conditions: Individuals with gastrointestinal disorders (e.g. Crohns disease ulcerative colitis) that may affect the absorption of Viton 99 Caplet or interfere with study outcomes.

Design outcomes

Primary

MeasureTime frame
Changes in physical endurance muscle strength flexibility and cognitive performance in healthy adults.Timepoint: 60 days

Secondary

MeasureTime frame
1.Dose efficacy relationship 2.Sleep Quality 3.Mental Health and Quality of loifeTimepoint: 60 days

Countries

India

Contacts

Public ContactDr Devyani Bhadlikar

Sardar Ajit Singh Smriti Ayurveda Mahavidyalaya Raisen Road Bhopal Madhya Pradesh

drdevyani.bhadlikar@gmail.com9920467783

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026